• Search
  • Advanced Search
Child Kidney Dis > Volume 30(1); 2026 > Article
Baek and Cho: Correction to "Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?"
Correction

Child Kidney Dis 2026;30(1):69-69.

Published online: January 12, 2026

DOI: https://doi.org/10.3339/ckd.23.021.c1

Correction to "Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?"

Hee Sun Baek1, Min Hyun Cho2

1Department of Pediatrics, Yeungnam University College of Medicine, Daegu, Republic of Korea

2Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Republic of Korea

© 2026 Korean Society of Pediatric Nephrology

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
Child Kidney Dis 2023;27(2):76-81.
In the article titled “Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?” [1] published December 31, 2023, errors were identified in an author name. The incorrect name has been corrected for accuracy. This article has been corrected online.

Reference

1. Baek HS, Cho MH. Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease? Child Kidney Dis 2023;27:76-8.
crossref
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 1,290 View
  • 32 Download
Related articles

Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?2023 December;27(2)

Editorial Office
#403 Blue, 240 Gimpohangang 1-ro, Gimpo 10078, Republic of Korea
TEL: +82-10-4391-0788   E-mail: chikd@chikd.org
© Korean Society of Pediatric Nephrology.         
Close layer